Clinical trial
A Study to Evaluate PT-523 in Patients With Refractory Leukemia
NCT00129558 · Spectrum Pharmaceuticals, Inc, Industry · Withdrawn
Key facts
| NCT number | NCT00129558 |
|---|---|
| Title | A Study to Evaluate PT-523 in Patients With Refractory Leukemia |
| Official title | A Phase I/II Study of PT-523 in Patients With Refractory Leukemia |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | PT-523 for Injection |
| Enrollment | 0 |
| Start date | Jul 1, 2005 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Aug 12, 2005 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: